Arcturus Therapeutics targets OTC deficiency with mRNA medicines at SSIEM 2026 event

Arcturus Therapeutics targets OTC deficiency with mRNA medicines at SSIEM 2026 event
Arcturus unveils mRNA at SSIEM 2026

Arcturus Therapeutics announced its participation in SSIEM 2026, which will take place from August 25 to 28.

The company will be available at Booth S11, where it plans to discuss its ongoing work in treating OTC deficiency using mRNA medicines. Arcturus Therapeutics aims to highlight advancements and engage with the scientific community at the event. Details about specific data or research outcomes were not included in the announcement.

Arcturus Therapeutics has previously taken part in major scientific conferences. The company attended the 39th National CF Education Conference to engage with the cystic fibrosis community. These events form part of Arcturus's ongoing effort to connect with stakeholders in rare disease research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.